



## Featured Article

# Alzheimer's disease in humans and other animals: A consequence of postreproductive life span and longevity rather than aging

Daniëlle Gunn-Moore<sup>a</sup>, Oksana Kaidanovich-Beilin<sup>b,1</sup>, María Carolina Gallego Iradi<sup>c</sup>,  
Frank Gunn-Moore<sup>d</sup>, Simon Lovestone<sup>e,\*</sup>

<sup>a</sup>University of Edinburgh, Royal (Dick) School of Veterinary Studies and The Roslin Institute, Easter Bush Campus, Roslin, UK

<sup>b</sup>AstraZeneca Canada, Mississauga, Ontario, Canada

<sup>c</sup>University of Florida, College of Medicine, Department of Neuroscience, Center for Translational Research in Neurodegenerative Diseases, Gainesville, FL, USA

<sup>d</sup>University of St Andrews, School of Biology, St Andrews, UK

<sup>e</sup>University of Oxford, Department of Psychiatry, Oxford, UK

**Abstract**

**Introduction:** Alzheimer's disease and diabetes mellitus are linked by epidemiology, genetics, and molecular pathogenesis. They may also be linked by the remarkable observation that insulin signaling sets the limits on longevity. In worms, flies, and mice, disrupting insulin signaling increases life span leading to speculation that caloric restriction might extend life span in man. It is our contention that man is already a long-lived organism, specifically with a remarkably high postfertility life span, and that it is this that results in the prevalence of Alzheimer's disease and diabetes.

**Methods:** We review evidence for this hypothesis that carries specific predictions including that other animals with exceptionally long postreproductive life span will have increased risk of both diabetes and Alzheimer's disease.

**Results and Conclusions:** We present novel evidence that Dolphin, like man, an animal with exceptional longevity, might be one of the very few natural models of Alzheimer's disease.

© 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

**Keywords:**

Longevity; Insulin signaling; Alzheimer's pathology; Animal models; Tau; Amyloid; GSK-3

**1. Diabetes mellitus and Alzheimer's disease**

As populations all over the world age, enormous challenges are posed by chronic disorders such as Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM). AD in particular is a devastating condition. With a long prodromal period of perhaps 10 to 20 years followed by another decade of clinical symptoms, AD and related dementia conditions are becoming a priority for many governments, not least as it is estimated that 1% of global gross domestic product is

spent on dementia care (<http://www.alz.co.uk/research/files/WorldAlzheimerReport2010.pdf>). As well as growing older, the populations of the developed economies are also growing obese and sedentary. Although this is most marked in the developed nations, it is truly an international trend, and as children in particular show dramatic increases in body mass index, this is a deeply concerning indicator of health problems to come. These health problems are significant as obesity increases risk of cancers, cardiovascular disease, and metabolic syndromes including T2DM.

These two health challenges—an aging population at risk of neurodegenerative disease such as AD and an increasingly obese population at risk of metabolic conditions such as T2DM—may seem unconnected and unfortunate consequences of modern civilization. It could be suggested that improved health care and sanitation leading to older populations, combined with seemingly unlimited

The authors have declared that no conflict of interest exists.

<sup>1</sup>Affiliated previously at Samuel Lunenfeld Research Institute, Toronto, Canada.

\*Corresponding author. Tel.: +44 (0) 1865 618230; Fax: +44 (0) 1865 793101.

E-mail address: [simon.lovestone@psych.ox.ac.uk](mailto:simon.lovestone@psych.ox.ac.uk)

<https://doi.org/10.1016/j.jalz.2017.08.014>

1552-5260/© 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

access to highly processed and calorific foods and an increasingly sedentary lifestyle, suggests entirely independent and environmental, or more specifically social and historical, causes of the twin challenges of AD and T2DM. It is our contention however that this construct is only partially explanatory and that there is a molecular link between longevity and both AD and T2DM that suggests a relationship whereby both arise not as an unfortunate consequence of growing older in the modern world but are intrinsic to it. In other words that AD and T2DM are conditions not of *aging* as they are usually considered, but of *longevity*. It is not so much how long an organism lives for that governs whether the organism is vulnerable in particular to AD, but the molecular mechanisms that underlie this period; a period that is highly characteristic for any given species. Moreover, that this longevity-associated disease risk explains why AD and T2DM are disorders principally of man. Here we propose a hypothesis that AD and T2DM are the price we pay for the molecular underpinning that allows us to be *almost uniquely* long-lived animals.

AD is a form of dementia characterized by two main pathological lesions, the amyloid plaque and the neurofibrillary tangle (NFT). Although it remains contentious whether these lesions are themselves causative of the neuronal loss that results in functional deficits or whether they are simply indicative of an underlying process, the evidence from molecular genetics and experimental neuroscience is compelling that the amyloid cascade is at the heart of the pathology of AD [1]. This cascade involves first the generation of amyloid  $\beta$  (A $\beta$ ) from the amyloid precursor protein (APP) and subsequently the aggregation of highly phosphorylated tau protein. Other processes including neuroinflammation clearly play a role, perhaps to exacerbate the amyloid cascade, perhaps triggered by the cascade, or perhaps independently. In addition to genetic causes of familial early-onset AD and genetic influences on late-onset AD, a considerable effort has been expended on searching for environmental influences on AD. Despite this, relatively few have been identified and arguably, other than age itself only two—head injury and obesity/diabetes—have been unambiguously replicated [2,3]. The evidence that diabetes and obesity increase the risk of dementia has been consistently reported from many epidemiological studies, themselves the subject of multiple systematic reviews [3–8]. The mechanism underlying this risk might be at multiple levels, the most parsimonious of which might be that metabolic complications increase vascular damage to the brain and this either exacerbates AD pathology or is an additive or independent insult [3]. However, insulin resistance predicts the development of cerebral amyloid pathology as measured by positron emission tomography imaging [9] and considerable evidence from cell and animal models suggests that a *failure of insulin signaling* directly contributes to AD pathological processes, including the formation of tau pathology as we discuss in the following sections.

## 2. Insulin actions: role of glycogen synthase kinase-3

For a failure of insulin signaling to effect the risk of AD directly rather than through a mediating factor such as vascular damage, then insulin resistance in the periphery should be reflected in insulin resistance in the brain. Considerable evidence suggests that this is in fact the case [10–12]. For example, in midlife, peripheral insulin resistance is associated with central glucose metabolic abnormality as well as with poorer cognitive performance [13,14] and predicts amyloid deposition [9]. In turn, there is evidence that central insulin signaling failure or abnormality can induce peripheral insulin resistance. In mice, ablation of insulin receptors (IRs) either from the whole brain (neuronal-specific IR knockout) or specifically from hypothalamus or midbrain dopamine neurons induces hyperphagia, body weight gain, and peripheral insulin resistance [15–17]. Also, brain-specific genetic inactivation of the insulin receptor substrate 2 (IRS2), that is essential for insulin signaling, results in obesity and diabetic phenotypes [18].

These data demonstrate a critical link between the central nervous system and the periphery, and importantly, both mice lacking the neuronal IR and those with IRS2 deleted are characterized by elevated tau phosphorylation and cognitive alterations, both are characteristics of AD [19,20]. Moreover, animal models of aspects of AD pathology show dysregulated metabolism [21] providing further experimental evidence for an intertwining of the molecular mechanisms of metabolic function and insulin signaling with AD. This link, and the increased risk of dementia in people with diabetes, suggests that there may be therapeutic opportunities for AD in enhancing insulin signaling, or tackling insulin resistance. Real-world data studies suggest that the commonly used therapy for T2DM, pioglitazone a PPAR $\gamma$  agonist that enhances insulin signaling, reduces the incidence of AD [22], and intranasal insulin beneficially alters APP processing and reduces cognitive impairment in early AD [23–25]. Large-scale trials of both intranasal insulin and pioglitazone are now underway. Although the outcomes of these trials are some years away, it is clear that systemic insulin signaling disruption increases the risk of AD and might do so through shared molecular mechanisms and not simply through end-organ damage as a consequence of vascular or other T2DM-induced pathology.

One such molecular mechanism that might plausibly underlie this link between insulin signaling in the brain and AD processes is mediated by glycogen synthase kinase-3 (GSK-3), initially discovered through its ability to phosphorylate glycogen synthase [26]. Given its critical role in insulin signaling, it is not surprising that GSK-3 has been implicated in the pathogenesis of obesity and insulin resistance [27,28], but it has also been shown to have a fundamental role in the pathogenesis of AD [29,30]. Tau is a physiological substrate of GSK-3, and transgenic mice with increased GSK-3

activity have neurodegeneration phenotypes including tau hyperphosphorylation and cognitive impairments [31]. Even before neurodegeneration sets in, GSK-3 overactivity suppresses long-term potentiation [32], while inhibition of GSK-3 is required following long-term potentiation to block long-term depression [33] suggesting that the normal regulation of GSK-3 is essential for synaptic plasticity [34]. If GSK-3 is altered in AD, then early neuronal dysfunction could be a consequence of this disruption of plasticity before tau becomes phosphorylated, aggregated and participates in pathological spread.

Given the role of GSK-3 in synaptic plasticity, as well as other functions of neurons such as axonal transport [35], then it is not surprising that these functions become perturbed in the context of metabolic dysfunction such as insulin resistance, resulting in neuronal dysfunction and—for example—cognitive impairment. The finding that a failure of insulin signaling also results in AD pathology is in line with the concept that these neuropathological features represent a final common pathway of disease with multiple influences including in this context insulin signaling but also potentially other processes such as a failure of calcium homeostasis for example [36].

### 3. Insulin signaling as a key regulator of longevity

This evidence powerfully argues for a role of insulin signaling and its downstream molecules, in particular perhaps GSK-3, in AD pathogenesis. It would explain, in part, the epidemiological evidence that insulin resistance conditions such as T2DM are risk factors for AD. Insulin signaling however is also, remarkably, associated with longevity. In worms, flies, and mice, perturbations in insulin signaling leading to decreased insulin response also lead to a substantially increased life span [37–40]. The increase in life span is considerable—in some animals a fold change in normal longevity and in mammals up to a 50% increase. Both caloric restriction resulting in a decreased responsiveness of the insulin signaling pathway and direct knockout of insulin signaling and its associated pathway genes have this effect. The effect is so large, and so consistent, that there are reports of people attempting to extend their own lives through caloric restriction, and many websites offer advice on how to do this with various levels of warning about the potential dangers of partial-starvation diets. Clearly, there is much to recommend avoiding obesity or even the moderate overweight state that is becoming the norm in the industrialized nations. Moreover, there is consistent evidence from two long primate studies and one long canine study for the benefits of caloric restriction on health, although they differ on whether caloric restriction increases life span in monkeys and dogs as it does in mice [41–44]. However, it remains to be seen, and remains highly controversial, as to whether caloric restriction will have effects on longevity in man.

### 4. Man as an exception to the longevity thesis

We believe that this argument, which regularly escapes into the nonscientific general media, is missing an important observation. Man is not like most other animals. Specifically, humans have a notably extended postfertility life span (PFLS). While some life beyond fertility is not uniquely human, indeed it is a characteristic shared with many mammalian species, as Cohen in his review of the relevant literature points out [45]. Nonetheless, even evaluating Cohen's own review data, it is clear that as a proportion of total life span, humans have a remarkable and highly extended PFLS. Women cease to become fecund at a maximum age of ~45 years, and life span in man is recorded to 110 years and more. Also from Cohen's review, only one other animal was identified with an extended PFLS similar to man—the killer whale, *Orcinus orca*, which has a total life span of twice the fertility span ([45]; Table 1). Theories abound regarding why man has such a remarkably extended PFLS, the most popular of which is the “grandmother hypothesis” variants of which suggest an evolutionary advantage to having members of a close-knit hunter-gatherer unit available for child caring and other societal functions [46]. Recently, similar reasoning has been extended beyond man to that other mammals with extended PFLS, *O. orca* [47–49], with a model demonstrating that improved reproductive success in younger individuals combined with the usefulness of non-fertile-related individuals provides a selection pressure that could account for the evolution of menopause and an extended postfertility life [50].

However, regardless of the evolutionary origins of PFLS, the link between longevity and the insulin signaling pathway and between insulin signaling and AD suggests a hypothesis. This is that increasing longevity is achieved through increases in PFLS, the molecular underpinning of which is a reduced “efficiency” of insulin and insulin-like growth factor signaling (IIS), and as a consequence of this reduced IIS, organisms with relatively increased PFLS are at relatively increased risk of AD. In such a hypothesis, the “efficiency” of IIS might refer to decreased tonic activity or control over the pathway or decreased response, for example, of insulin to metabolic stimulus or of cell response to signaling, or some combination thereof. Whatever the specific mediators of the general mechanism of “efficiency of IIS”, the hypothesis we propose here brings some specific predictions. Most obvious, and most testable, is the prediction that the molecular and pathological characteristics of AD will be more common in animals with a relatively longer PFLS as a proportion of total life span. In other words, that plaques and tangles and associated molecular events will be correlated *not with age per se but with longevity*. We would predict the features of AD to be associated more with PFLS than with life span and to be a disease not only of man but of other animals with a long PFLS, specifically, to be a disease in animals such as *O. orca* more than of our closer relatives, such as the chimpanzee.

Table 1

Life span and reproductive span across a range of animals (adapted from Cohen [45]) with the two outlier species with exceptionally long in PFLS in bold

Order	Scientific name	Common name	Maximum recorded lifespan (years)	Mean PFLS (years)	PFLS as a % of maximum life span
Artiodactyla	<i>Bos primigenius</i>	Cattle	30	5	16.7
	<i>Cervus elaphus</i>	Red deer	21	3	14.3
	<i>Ovis canadensis</i>	Bighorn sheep	19	2	10.5
Carnivora	<i>Canis domesticus</i>	Domestic dog (beagle)	15	3.5	23.3
	<i>Felis silvestris catus</i>	Domestic cat	21*	8	38
	<i>Panthera leo</i>	African lion	17	1.8	10.6
	<i>Ursus maritimus</i>	Polar bear	30	4	13.3
Carnivora Cetacea	<i>Globicephalus macrorhynchus</i>	Short-finned pilot whale	63	14	22.2
	<i>Orcinus orcus</i>	Killer whale	<b>78</b>	<b>38</b>	<b>48.7</b>
Primates	<i>Callithrix jacchus</i>	Common marmoset	10	2	20.0
	<i>Gorilla gorilla</i>	Gorilla	30	4.5	15.0
	<i>Lemur spp.</i>	Lemurs (five spp.)	24	3.5	14.6
	<i>Leontopithecus rosalia</i>	Golden lion tamarin	12	4	33.3
	<i>Macaca fuscata</i>	Japanese macaque	35	4.5	12.9
	<i>Macaca mulatta</i>	Rhesus macaque	35	2.5	7.1
	<i>Macaca nemestrina</i>	Pig-tailed macaque	30	4	13.3
	<i>Macaca radiata</i>	Bonnet macaque	20	6	30.0
	<i>Macaca sylvanu</i>	Barbary macaque	28	5	17.9
	<i>Pan troglodytes</i>	Common chimpanzee	48	9	18.8
	<i>Papio cynocephalus</i>	Olive baboon	27	5	18.5
	<i>Papio cynocephalus/anubis</i> hybrids	Baboon	16	3.5	21.9
	<i>Saguinus fuscicollis</i>	Saddleback tamarin	12	4	33.3
	<i>Saimiri sciureus</i>	Squirrel monkey	19	3.5	18.4
		<i>Homo sapiens</i>	Man	<b>110</b>	<b>45</b>

Abbreviations: PFLS, postfertility life span; PRLS, postreproductive life span.

NOTE. Cohen (1994) lists the mean PRLS (equivalent to the PFLS used in the text of this article and in this table) for a range of animals together with their maximum observed life span. Here we extract from Cohen those where these data are known and have, where a range is given, listed the mean value, and in addition expressed the PFLS as a proportion of life span. We add data for man, and assume that 110 years is a maximum life span, although older people have been recorded, and for PFLS have assumed a mean age at death of 85 years and a mean age of reproductive cessation of 40 years (see [http://en.wikipedia.org/wiki/Age\\_and\\_female\\_fertility](http://en.wikipedia.org/wiki/Age_and_female_fertility) for discussion of age of fertility).

\*But very occasional much older cats have been found, e.g., 32 years of age (seen by author D.G.-M.). Importantly, long-live cats are typically neutered.

## 5. Do cetaceans, or other diving animals, have dementia?

We are unaware of any data on AD pathology, let alone cognitive and functional impairment in *O. orca*. However, a related cetacean, *Stenella coeruleoalba*, the striped dolphin, has an average life span of ~58 years, and the females drop fecundity at 30 years giving them a PFLS of ~48 (Prof V. Janik, Scottish Oceans Institute, University of St Andrews, personal communication), similar to the killer whale. Therefore, we set out to examine this hypothesis predicting that an animal with a long PFLS would have evidence of AD pathology hitherto not identified in free-living, wild animals. To do this, we obtained eight brains from stranded dolphins from different coastal areas of Spain. RNA extraction from this material allowed the identification of the coding region of the APP gene covering the 40–43 amino acid region of the A $\beta$  peptide and was shown to be identical across three species of dolphins, *Tursiops truncatus* (bottlenose dolphin), *Grampus griseus* (Risso's dolphin), and *S. coeruleoalba*, and man (Fig. 1A), suggesting that these species of dolphins could generate A $\beta$  from the precursor protein. Three specimens belonging to *S. coeruleoalba* species were immunopositive for amyloid plaques and four (3 *S. coeruleoalba* and

1 *T. truncatus* species) for tau fibrillary tangles. Specifically, two types of amyloid deposits were visualized: firstly in the parietal cortex as diffuse deposits, and secondly in the cerebellum, the region of the brain used for echo-location, where there were structures that resembled more compact senile plaques (Fig. 1B). These latter amyloid deposits were up to 50  $\mu$ m in diameter, and in some areas, the plaques were relatively numerous. Neurites surrounding these plaques were immunopositive for tau, similar to that seen in cortical amyloid deposits in humans. In the frontal cortex, as well as in the parietal cortex, thalamus, and cerebellum, there was evidence of tau pathology, for example, seen as well-defined neurofibrillary threads in the cortex of an adult animal (Fig. 1C). In summary, these studies found evidence of both amyloid deposits and tau pathology in stranded dolphins including in the same individuals (Fig. 1E), making this animal one of very few naturally occurring models of an almost uniquely human disease. Clearly, it would be of considerable interest to know whether the pathology we observe in these animals had effects on cognition and indeed on behavior, and although such studies are unlikely to be achievable in wild animals, it may be possible to determine the relationship between AD-like pathology




Fig. 1. Alzheimer pathology in striped dolphin (*Stenella coeruleoalba*) brain. (A) A $\beta$ 42 amino acid alignment between three dolphin species and other mammals. (B) Amyloid plaques in cerebellum tissues from a *S. coeruleoalba* specimen, AB2 (Araclon Biotech antibody, 1:750 specific for human amyloid  $\beta$  40). (C) Amyloid plaque in the parietal cortex from *S. coeruleoalba* AB2 (Araclon Biotech antibody, 1:750 specific for human amyloid  $\beta$  40). (D) Neurofibrillary tangles in the frontal cortex of *S. coeruleoalba*, 5A6 antibody (Hybridoma Bank, 1:750). (E) Neurofibrillary threads and plaques in the parietal cortex of a single *S. coeruleoalba* specimen, 5A6 antibody (Hybridoma Bank, 1:750).

and function in captive individuals. We note also with considerable interest that dolphins are also prone to T2DM, showing blood-based indicators of insulin resistance [51] and possibly being a natural model of metabolic syndrome [52]. Although this is in line with our hypothesis, we cannot know if the individuals in this case had such deficits in insulin signaling and response in part because the reference values for dolphin are less certain and in part because analysis of postmortem samples for analytes such as glucose and insulin is challenging in man [53,54] and, to our knowledge, not informative in cetaceans.

These findings suggest that full AD pathology, as well as T2DM, can occur in free-living, wild cetaceans. In addition, recent evidence suggests other changes, perhaps

indicative of early AD, can be found in other sea mammals. Investigating the stranding and death of sea lions suffering from domoic acid toxicosis due to blue-green algae, it has been reported that cerebrospinal fluid (CSF) from these animals shows evidence of changes indicative of neurodegeneration [55]. Using untargeted mass spectrometry proteomics methods, Neely et al found an excess of multiple-complement proteins and gelsolin, proteins we and others have reported to be associated with AD [56,57]. Other proteins found in the CSF of these animals include *neuronal cell adhesion molecule* and *reelin*, both proteins previously having been implicated in AD pathology [58,59]. Even more remarkably to our mind is the observation of altered Dickkopf 3 protein

(DKK3) in sea lions' CSF in that study. This is of considerable interest as the DKK proteins are the predominant negative regulators of Wnt signaling, the final effector of which is GSK-3 suggesting a possible link to both insulin signaling and to AD pathogenesis. Evidence for a role of DKK in AD abounds. DKK1 is increased by A $\beta$  in human brain and in animal models [60], inhibition or silencing DKK1 prevents A $\beta$ -induced synaptic loss [61], and we have shown DKK induction by A $\beta$  transmits the toxic signal through clusterin to not only neurotoxicity but also tau phosphorylation and cognitive impairment [62]. Not surprisingly, given these findings, DKK1 is now of considerable interest as a target for therapy [63]. Most of these studies have focused on DKK1 but not excluded the involvement of the other, highly similar, DKK proteins; however, in at least one study, DKK3 colocalized with A $\beta$  pathology in AD brain [64] and was increased in CSF and plasma of people with AD [65].

## 6. AD: Just how common is it (in other animals)?

The finding of both amyloid and tau pathology in dolphins, as we reported previously, is all the more remarkable an observation as AD pathology has only been rarely reported in other mammals [66]. In a recent, detailed and comprehensive review of the aging brain in nonhuman animals, Youssef et al [66] find evidence of *some* features of human neurodegenerative disease in many animals, although note considerable differences from human disease and the absence of a natural model linking the twin features of AD (plaques and tangles) with each other and neuronal loss and with cognitive impairment. Specifically, they note that highly phosphorylated tau but not NFTs are found in sheep, goats, cheetah, bison, baboons, and bears. Closer to man, nonhuman primates, including chimpanzee, orangutan, gorilla, baboon, rhesus, cynomolgus, and green monkeys are all found to have amyloid plaques but not NFTs (Youssef et al [66]; Table 1)

Just as in many of these animals, previous studies have found evidence in dogs (cross-breeds and beagles) of amyloid, but not tau pathology [66]. Cohen (Table 1) indicates that dogs (beagles) have a PFLS of 23.3, though in reality this is breed specific [67,68], and some families of beagles may be prone to premature senility and develop amyloid deposits but not neuritic plaques [69,70]. Our hypothesis that PFLS associates with AD pathology would predict that breeds with a longer PFLS than beagle would be likely to have more AD pathology including neuritic plaques.

The domestic cat has a longer PFLS than dog, of 38 or more (Gunn-Moore, 2016 personal experience), and with reference to T2DM, domestic cats show pathology signs more akin to humans than any other nonprimates [71]. Moreover, cats develop early amyloid changes but not pla-

ques [72,73]. Although in unpublished findings noted in Youssef et al [66], Nakayama reports neuronal cell loss in the hippocampus of aged cats associated with NFTs composed of highly phosphorylated tau. In a recent comprehensive neuropathological study, Chambers et al, quite remarkably, found the full extent of AD pathology and proposed the cat as a natural model of Alzheimer's [74]. In the context of the cat, many pet animals are neutered, and as such their fecundity will have been dramatically reduced, while their PFLS will have been markedly increased. Importantly, neutering increases not only longevity in our pets but also their risk of obesity, and as mentioned previously in relation to cats, an increase in T2DM. It is not known whether this increase in obesity and T2DM in neutered animals reflects the critical change in "IIS efficiency" we postulate to be the molecular mechanism underlying the association between PFLS and AD or whether it is central as well as systemic. However, our hypothesis would suggest that, to the extent that it does, then evidence of AD pathology would be present in aged neutered cats. Just as interbreed studies in dog might be a means to test the hypothesis, then studies in neutered cats might be a means to test the underlying molecular mechanisms.

## 7. Conclusions and some suggestions for further study

In summary then, the findings we report and review here suggest that, almost uniquely other than in man, sea mammals and cats might have AD-like neurodegeneration. This ranges from sea lions with domoic acid toxicosis having CSF markers also found in AD to postmortem amyloid and tau pathology in the brains of dolphins. Moreover, dolphins are uniquely prone to a (pre) diabetes state and are one of the few animals, alongside other cetaceans and man with a naturally long postfertility life span. Cats have both T2DM and recent evidence suggests full AD pathology, and also they have a moderately long PFLS albeit not as long as man and *O. orca*. Is this sharing of AD pathology, diabetes, and PFLS important? We suggest it is, and this then is our hypothesis: humans, at some point in our evolutionary history, acquired an insulin pathway trait characteristic that makes it less responsive to external signaling or less effective in transmitting this signal to targets generally or to GSK-3 specifically. This characteristic results in longer life relative to other animals but also the twin diseases of T2DM and AD (Fig. 2). This hypothesis does not imply that insulin signaling affects only longevity, that the effects of insulin signaling on metabolism, longevity, and dementia are necessarily mediated through a single mechanism, and even that defects in IIS inevitably result in dementia. Clearly, there might be independent mechanisms at play and indeed for such a critical signaling pathway with pleiotropic actions on fundamental processes of physiology, it would be




Fig. 2. Insulin signaling protects against AD at the cost of longevity. We postulate that for a given stimulus, the response of the insulin signaling pathway from generation of ligand through intracellular signaling to the effector of the pathway in the action of GSK-3, which is inhibited by insulin signaling, varies giving a relative response that we characterize as “efficient” or “inefficient”. Species-level differences in the efficiency of response to stimulus will influence the relative life span, risk of T2DM, and risk of AD; a highly efficient response resulting in relatively shorter life span but reduced risk of T2DM and AD, whereas a less-efficient response increases PFLS and hence longevity but at the expense of risk of T2DM and AD. Note that this hypothesis emphasizes that the “efficiency” of the insulin response system is as likely to be the actor in the evolutionary pressure resulting in longevity in man and *Orcinus orca* as the fact that we are both long-lived animals. Abbreviations: AD, Alzheimer’s disease; APP, amyloid precursor protein; GSK-3, glycogen synthase kinase-3; IGF, insulin-like growth factor; PFLS, postfertility life span; T2DM, type 2 diabetes mellitus.

surprising if there were not independent influences on processes such as metabolism, longevity, and dementia. However, here we postulate a linked mechanism that led us to hypothesize that animals with unusual longevity would be at risk of both insulin resistance and AD, a hypothesis that led us to a prediction that cetaceans and cats would have AD pathology—a prediction for which we have provided some proof.

This hypothesis has important consequences for our explanatory constructs of human evolution and also some testable predictions. First, in evolutionary theory, there has been a robust debate regarding the PFLS in man with some arguing for the competitive advantages offered by the elder in early human societies—the so-called grandmother hypothesis [75]. Our proposal suggests that this theory might be arguing after the effect and the evolutionary driver may have been at a molecular level and theorists might productively search instead for a competitive advantage offered by a relatively less “efficient” or responsive IIS pathway. Second, in terms of predictions that follow from our hypothesis, we would suggest that AD and T2DM would be relatively less common in nonhuman mammals and moreover, pathological features of both dis-

eases would occur most often in those animals with a relatively longer PFLS. Some aspects of AD pathology have been reported in a wide range of other animals, although in almost all cases this is very incomplete making our report here of both neuritic plaque and tangle pathology in dolphin all the more remarkable. Further studies including large variable biomolecular studies, such as those that have recently been reported in sea lions, will be of interest in exploring the relationship between AD pathology and vulnerability to metabolic dysfunction in sea mammals and cats. However, testing the prediction that follows from our hypothesis quantitatively from such case reports from wild cetaceans is difficult, and we would not advocate the use of captive cetaceans as experimental animals. So we propose a specific experiment. Recombinant inbred strain mice show both variation in life span and life span response to caloric restriction [76]. Our hypothesis would suggest that these traits would be associated with insulin signaling phenotypes and moreover, and more surprisingly, with phenotypes relevant to AD such as A $\beta$  generation, tau expression, and phosphorylation. Finally, a word to those individuals practicing caloric restriction to extend life span, “If we are right, then it’s too late; we are already

long-lived animals and the price we pay is Alzheimer's disease".

### Acknowledgments

Research in the author's laboratories is supported by the NIHR, MRC, ARUK, Alzheimer's Society, Wellcome Trust, and the EU.

### RESEARCH IN CONTEXT

1. Systematic review: In rodent models, amyloid generation does not induce tau pathology and neuronal loss, and although some aspects of AD are found in a variety of animals, there is no instance of full pathology in a wild animal. This suggests man is uniquely vulnerable to Alzheimer's. The authors also note that man is a uniquely long-lived animal primarily in respect of postfertility life span. Finally, systematic reviews have shown that failure in insulin signaling (type 2 diabetes) increases risk of AD and also increases longevity.
2. Interpretation: These observations lead to the proposal that other animals with postreproductive life span similar to man might also be vulnerable to AD. The authors explore this in long-living cetaceans, providing evidence that stranded Dolphins have both plaque and tangle pathology; the first time this has been observed in a wild animal.
3. Future directions: This evidence together with evidence for AD pathology in domesticated long-lived animals (e.g., cat) provides a clear pathway to developing better, more predictive animal models.

### References

- [1] Hardy J. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? *Curr Alzheimer Res* 2006;3:71–3.
- [2] Fleminger S, Oliver DL, Lovestone S, Rabe-Hesketh S, Giora A. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. *J Neurol Neurosurg Psychiatry* 2003;74:857–62.
- [3] Vagelatos NT, Eslick GD. Type 2 diabetes as a risk factor for Alzheimer's disease: the confounders, interactions, and neuropathology associated with this relationship. *Epidemiol Rev* 2013;35:152–60.
- [4] Xu W, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. Meta-analysis of modifiable risk factors for Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2015;86:1284–5.
- [5] Meng XF, Yu JT, Wang HF, Tan MS, Wang C, Tan CC, et al. Midlife vascular risk factors and the risk of Alzheimer's disease: a systematic review and meta-analysis. *J Alzheimers Dis* 2014;42:1295–310.
- [6] Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. *PLoS One* 2009;4:e4144.
- [7] Kopf D, Frolich L. Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. *J Alzheimers Dis* 2009;16:677–85.
- [8] Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. *Lancet Neurol* 2006;5:64–74.
- [9] Willette AA, Johnson SC, Birdsill AC, Sager MA, Christian B, Baker LD, et al. Insulin resistance predicts brain amyloid deposition in late middle-aged adults. *Alzheimers Dement* 2015;11:504–510.e1.
- [10] Schiöth HB, Craft S, Brooks SJ, Frey WH 2nd, Benedict C. Brain insulin signaling and Alzheimer's disease: current evidence and future directions. *Mol Neurobiol* 2012;46:4–10.
- [11] Kullmann S, Heni M, Hallschmid M, Fritsche A, Preissl H, Haring HU. Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. *Physiol Rev* 2016;96:1169–209.
- [12] Craft S. Alzheimer disease: insulin resistance and AD—extending the translational path. *Nat Rev Neurol* 2012;8:360–2.
- [13] Willette AA, Bendlin BB, Starks EJ, Birdsill AC, Johnson SC, Christian BT, et al. Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease. *JAMA Neurol* 2015;72:1013–20.
- [14] Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. *Arch Neurol* 2011;68:51–7.
- [15] Obici S, Feng Z, Karkanias G, Baskin DG, Rossetti L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. *Nat Neurosci* 2002;5:566–72.
- [16] Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, et al. Role of brain insulin receptor in control of body weight and reproduction. *Science* 2000;289:2122–5.
- [17] Konner AC, Hess S, Tovar S, Mesaros A, Sanchez-Lasheras C, Evers N, et al. Role for insulin signaling in catecholaminergic neurons in control of energy homeostasis. *Cell Metab* 2011;13:720–8.
- [18] Taguchi A, Wartschow LM, White MF. Brain IRS2 signaling coordinates life span and nutrient homeostasis. *Science* 2007;317:369–72.
- [19] Schubert M, Gautam D, Surjo D, Ueki K, Baudier S, Schubert D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. *Proc Natl Acad Sci U S A* 2004;101:3100–5.
- [20] Killick R, Scales G, Leroy K, Causevic M, Hooper C, Irvine EE, et al. Deletion of *Irs2* reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. *Biochem Biophys Res Commun* 2009;386:257–62.
- [21] Ruiz HH, Chi T, Shin AC, Lindtner C, Hsieh W, Ehrlich M, et al. Increased susceptibility to metabolic dysregulation in a mouse model of Alzheimer's disease is associated with impaired hypothalamic insulin signaling and elevated BCAA levels. *Alzheimers Dement* 2016;12:851–61.
- [22] Heneka MT, Fink A, Doblhammer G. Effect of pioglitazone medication on the incidence of dementia. *Ann Neurol* 2015;78:284–94.
- [23] Freiherr J, Hallschmid M, Frey WH 2nd, Brunner YF, Chapman CD, Holscher C, et al. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. *CNS Drugs* 2013;27:505–14.
- [24] Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. *J Alzheimers Dis* 2015;44:897–906.
- [25] Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. *J Alzheimers Dis* 2008;13:323–31.
- [26] Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. *Eur J Biochem* 1980;107:519–27.

- [27] Kaidanovich O, Eldar-Finkelman H. The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. *Expert Opin Ther Targets* 2002;6:555–61.
- [28] MacAulay K, Woodgett JR. Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes. *Expert Opin Ther Targets* 2008;12:1265–74.
- [29] Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. *J Neurochem* 2008;104:1433–9.
- [30] Kremer A, Louis JV, Jaworski T, Van Leuven F. GSK3 and Alzheimer's Disease: Facts and Fiction. *Front Mol Neurosci* 2011;4:17.
- [31] Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. *EMBO J* 2001;20:27–39.
- [32] Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. *Eur J Neurosci* 2007;25:81–6.
- [33] Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. *Neuron* 2007;53:703–17.
- [34] Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto ZA, Wang YT, et al. The role of GSK-3 in synaptic plasticity. *Br J Pharmacol* 2008;153:S428–37.
- [35] Morfini G, Pigino G, Beffert U, Busciglio J, Brady ST. Fast axonal transport misregulation and Alzheimer's disease. *Neuromolecular Med* 2002;2:89–99.
- [36] Alzheimer's Association Calcium Hypothesis W. Calcium Hypothesis of Alzheimer's disease and brain aging: A framework for integrating new evidence into a comprehensive theory of pathogenesis. *Alzheimers Dement* 2017;13:178–182.e17.
- [37] Kirkwood TB. Genes that shape the course of ageing. *Trends Endocrinol Metab* 2003;14:345–7.
- [38] Barbieri M, Bonafe M, Franceschi C, Paolisso G. Insulin/IGF-I signaling pathway: an evolutionarily conserved mechanism of longevity from yeast to humans. *Am J Physiol Endocrinol Metab* 2003;285:E1064–71.
- [39] Piper MD, Selman C, McElwee JJ, Partridge L. Separating cause from effect: how does insulin/IGF signalling control lifespan in worms, flies and mice? *J Intern Med* 2008;263:179–91.
- [40] Partridge L, Piper MD, Mair W. Dietary restriction in *Drosophila*. *Mech Ageing Dev* 2005;126:938–50.
- [41] Mattison JA, Roth GS, Beasley TM, Tilmont EM, Handy AM, Herbert RL, et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. *Nature* 2012;489:318–21.
- [42] Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. *Science* 2009;325:201–4.
- [43] Huck JL, Biery DN, Lawler DF, Gregor TP, Runge JJ, Evans RH, et al. A longitudinal study of the influence of lifetime food restriction on development of osteoarthritis in the canine elbow. *Vet Surg* 2009;38:192–8.
- [44] Lawler DF, Larson BT, Ballam JM, Smith GK, Biery DN, Evans RH, et al. Diet restriction and ageing in the dog: major observations over two decades. *Br J Nutr* 2008;99:793–805.
- [45] Cohen AA. Female post-reproductive lifespan: a general mammalian trait. *Biol Rev Camb Philos Soc* 2004;79:733–50.
- [46] Hawkes K, Coxworth JE. Grandmothers and the evolution of human longevity: a review of findings and future directions. *Evol Anthropol* 2013;22:294–302.
- [47] Brent LJ, Franks DW, Foster EA, Balcomb KC, Cant MA, Croft DP. Ecological knowledge, leadership, and the evolution of menopause in killer whales. *Curr Biol* 2015;25:746–50.
- [48] Foster EA, Franks DW, Mazzi S, Darden SK, Balcomb KC, Ford JK, et al. Adaptive prolonged postreproductive life span in killer whales. *Science* 2012;337:1313.
- [49] Whitehead H. Life history evolution: what does a menopausal killer whale do? *Curr Biol* 2015;25:R225–7.
- [50] Croft DP, Johnstone RA, Ellis S, Natrass S, Franks DW, Brent LJ, et al. Reproductive Conflict and the Evolution of Menopause in Killer Whales. *Curr Biol* 2017;27:298–304.
- [51] Venn-Watson S, Smith CR, Stevenson S, Parry C, Daniels R, Jensen E, et al. Blood-based indicators of insulin resistance and metabolic syndrome in bottlenose dolphins (*Tursiops truncatus*). *Front Endocrinol* 2013;4:136.
- [52] Venn-Watson S, Carlin K, Ridgway S. Dolphins as animal models for type 2 diabetes: sustained, post-prandial hyperglycemia and hyperinsulinemia. *Gen Comp Endocrinol* 2011;170:193–9.
- [53] Palmiere C, Sabatasso S, Torrent C, Rey F, Werner D, Bardy D. Post-mortem determination of insulin using chemiluminescence enzyme immunoassay: preliminary results. *Drug Test Anal* 2015;7:797–803.
- [54] Ojanpera I, Sajantila A, Vinogradova L, Thomas A, Schanzer W, Thevis M. Post-mortem vitreous humour as potential specimen for detection of insulin analogues by LC-MS/MS. *Forensic Sci Int* 2013;233:328–32.
- [55] Neely BA, Soper JL, Gulland FM, Bell PD, Kindy M, Arthur JM, et al. Proteomic analysis of cerebrospinal fluid in California sea lions (*Zalophus californianus*) with domoic acid toxicosis identifies proteins associated with neurodegeneration. *Proteomics* 2015;15:4051–63.
- [56] Baird AL, Westwood S, Lovestone S. Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology. *Front Neurol* 2015;6:236.
- [57] Aiyaz M, Lupton MK, Proitsi P, Powell JF, Lovestone S. Complement activation as a biomarker for Alzheimer's disease. *Immunobiology* 2012;217:204–15.
- [58] Botella-Lopez A, Burgaya F, Gavin R, Garcia-Ayllon MS, Gomez-Tortosa E, Pena-Casanova J, et al. Reelin expression and glycosylation patterns are altered in Alzheimer's disease. *Proc Natl Acad Sci U S A* 2006;103:5573–8.
- [59] Aisa B, Gil-Bea FJ, Solas M, Garcia-Alloza M, Chen CP, Lai MK, et al. Altered NCAM expression associated with the cholinergic system in Alzheimer's disease. *J Alzheimers Dis* 2010;20:659–68.
- [60] Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A, et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. *J Neurosci* 2004;24:6021–7.
- [61] Purro SA, Galli S, Salinas PC. Dysfunction of Wnt signaling and synaptic disassembly in neurodegenerative diseases. *J Mol Cell Biol* 2014;6:75–80.
- [62] Killick R, Ribe EM, Al-Shawi R, Malik B, Hooper C, Fernandes C, et al. Clusterin regulates beta-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway. *Mol Psychiatry* 2014;19:88–98.
- [63] Wan W, Xia S, Kalionis B, Liu L, Li Y. The role of Wnt signaling in the development of Alzheimer's disease: a potential therapeutic target? *BioMed Res Int* 2014;2014:301575.
- [64] Bruggink KA, Kuiperij HB, Gloerich J, Otte-Holler I, Rozemuller AJ, Claassen JA, et al. Dickkopf-related protein 3 is a potential Abeta-associated protein in Alzheimer's Disease. *J Neurochem* 2015;134:1152–62.
- [65] Zenzmaier C, Marksteiner J, Kiefer A, Berger P, Humpel C. Dkk-3 is elevated in CSF and plasma of Alzheimer's disease patients. *J Neurochem* 2009;110:653–61.
- [66] Youssef SA, Capucchio MT, Rofina JE, Chambers JK, Uchida K, Nakayama H, et al. Pathology of the Aging Brain in Domestic and Laboratory Animals, and Animal Models of Human Neurodegenerative Diseases. *Vet Pathol* 2016;53:327–48.
- [67] Creevy KE, Austad SN, Hoffman JM, O'Neill DG, Promislow DE. The Companion Dog as a Model for the Longevity Dividend. *Cold Spring Harb Perspect Med* 2016;6:a026633.

- [68] Hasegawa D, Yayoshi N, Fujita Y, Fujita M, Orima H. Measurement of interthalamic adhesion thickness as a criteria for brain atrophy in dogs with and without cognitive dysfunction (dementia). *Vet Radiol Ultrasound* 2005;46:452–7.
- [69] Wisniewski T, Lalowski M, Bobik M, Russell M, Strosznajder J, Frangione B. Amyloid  $\alpha$  1-42 deposits do not lead to Alzheimer's neuritic plaques in aged dogs. *Biochem J* 1996;313:575–80.
- [70] Russell MJ, White R, Patel E, Markesbery WR, Watson CR, Geddes JW. Familial influence on plaque formation in the beagle brain. *Neuroreport* 1992;3:1093–6.
- [71] O'Brien TD. Pathogenesis of feline diabetes mellitus. *Mol Cell Endocrinol* 2002;197:213–9.
- [72] Gunn-Moore DA, McVee J, Bradshaw JM, Pearson GR, Head E, Gunn-Moore FJ. Ageing changes in cat brains demonstrated by beta-amyloid and AT8-immunoreactive phosphorylated tau deposits. *J Feline Med Surg* 2006;8:234–42.
- [73] Gunn-Moore D, Moffat K, Christie LA, Head E. Cognitive dysfunction and the neurobiology of ageing in cats. *J Small Anim Pract* 2007;48:546–53.
- [74] Chambers JK, Tokuda T, Uchida K, Ishii R, Tatebe H, Takahashi E, et al. The domestic cat as a natural animal model of Alzheimer's disease. *Acta Neuropathol Commun* 2015;3:78.
- [75] Hawkes K. Grandmothers and the evolution of human longevity. *Am J Hum Biol* 2003;15:380–400.
- [76] Liao CY, Rikke BA, Johnson TE, Diaz V, Nelson JF. Genetic variation in the murine lifespan response to dietary restriction: from life extension to life shortening. *Aging cell* 2010;9: 92–5.